Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria
Spin-out from the Universities of Glasgow and Oxford
21-Nov-2023 -
Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria. The Company will use ...
antibiotic resistance
antibiotics
antimicrobial resistance
+5